{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:16:25Z","timestamp":1784200585091,"version":"3.55.0"},"reference-count":32,"publisher":"Innovative Healthcare Institute","issue":"2","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The use of allogeneic peripheral blood stem cell transplantation (allo-SCT) has increased in Latin America in recent years. In the absence of an matched-related donor (MRD), haploidentical transplantation has emerged as a potentially curative option with increasing availability in the region. Graft-versus-host disease (GVHD) is an important complication with variable incidence rates depending on the type of transplant. The aim of this study was to compare the incidence of acute and chronic GVHD between haploidentical and identical allo-SCT recipients and to analyze factors associated with the development of GVHD during the first year after transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our retrospective cohort study included adult patients with malignant and nonmalignant hematologic pathologies who received allo-SCT between 2014 and 2022 at a transplant center in Bogota, Colombia. Uni- and multivariate analyses were performed to determine factors associated with the development of GVHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 152 patients were analyzed, including 108 (71%) transplants from an MRD and 44 (28.9%) transplants from a haploidentical donor. The median age was 45 years. The most common indications for transplantation were acute myeloid leukemia (37.5%) and acute lymphoblastic leukemia (36.2%). The incidence of acute GVHD was greater in the haploidentical transplant group (63.0%) than in the MRD group (36.6%) (p &amp;lt; 0.05). There was no significant difference in the incidence of chronic GVHD between the two groups, with 18% and 33% in transplants from haploidentical donors and MRD, respectively (p = 0.09). The factors associated with the development of acute GVHD were relapse (odds ratio [OR] 0.41; 95% CI, 0.13\u20131.16), female sex (OR 2.34; 95% CI, 0.93\u20136.1), and age older than 50 years (OR 2.1; 95% CI, 0.81\u20135.71). The factors associated with the development of chronic GVHD were haploidentical donor status (OR 0.22; 95% CI, 0.05\u20130.75) and relapse (OR 0.16; 95% CI, 0.04\u20130.56).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study revealed a higher rate of acute GVHD in transplant recipients from a haploidentical donor than in those from MRD, whereas no differences were found for chronic GVHD between the two groups. Sex, age, relapse, and type of transplant were identified as factors associated with the prevalence of GVHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-24-25","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T02:29:07Z","timestamp":1739240947000},"page":"99-107","source":"Crossref","is-referenced-by-count":3,"title":["Incidence and Factors Associated with Graft-Versus-Host Disease in the First Year After Allogeneic Peripheral Blood Stem Cell Transplantation"],"prefix":"10.36401","volume":"8","author":[{"given":"Ulrike","family":"Heider","sequence":"first","affiliation":[{"name":"1 Division of Haematology, Blood Marrow Transplantation Unit, Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Solano-Vega","sequence":"additional","affiliation":[{"name":"1 Division of Haematology, Blood Marrow Transplantation Unit, Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-3650","authenticated-orcid":true,"given":"Y. Gisella","family":"Sandoval-Vargas","sequence":"additional","affiliation":[{"name":"2 Department of Internal Medicine, Faculty of Medicine, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ndida","family":"D\u00edaz-Brochero","sequence":"additional","affiliation":[{"name":"2 Department of Internal Medicine, Faculty of Medicine, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogot\u00e1, Colombia"},{"name":"3 Department of Epidemiology and Biostatistics, Faculty of Medicine, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"2025021107290065600_i2590-017X-8-2-99-b01","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2352-3026(20)30410-5","article-title":"The state of hematopoietic cells transplantation in Latin America","volume":"8","author":"Jaimovich","year":"2021","journal-title":"Lancet Hematol"},{"key":"2025021107290065600_i2590-017X-8-2-99-b02","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41409-022-01630-9","article-title":"Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012","volume":"57","author":"Correa","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b03","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41409-021-01431-6","article-title":"Hematopoietic stem cell transplantation activity in China: a report from the Chinese Blood and Marrow Transplantation Registry Group","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b04","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.bbmt.2020.07.035","article-title":"Differences in graft-versus-host disease characteristics between haploidentical transplantation using post-transplantation cyclophosphamide and matched unrelated donor transplantation using calcineurin inhibitors","volume":"26","author":"Solh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b05","first-page":"251","article-title":"Incidence of acute graft-versus-host disease in the patients with matched sibling donor hematopoietic stem cell transplant at a medical center","volume":"27","author":"Guar\u00edn-Casta\u00f1eda,","year":"2023","journal-title":"Rev Colomb Cancerol"},{"key":"2025021107290065600_i2590-017X-8-2-99-b06","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nature Rev Dis Primers"},{"key":"2025021107290065600_i2590-017X-8-2-99-b07","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2013NIH\u2013CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b08","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.bbmt.2019.12.570","article-title":"Comparison between allogeneic stem cell transplantation from unmanipulated haploidentical, unrelated and matched related donors for acute lymphoblastic leukemia and acute myeloid leukemia: experience in a single center in Colombia","volume":"26","author":"Figueroa","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b09","doi-asserted-by":"crossref","first-page":"1332181","DOI":"10.3389\/frtra.2024.1332181","article-title":"Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease\u2014an analysis from transplant centers across Europe","volume":"3","author":"L-anger","year":"2024","journal-title":"Front Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025021107290065600_i2590-017X-8-2-99-b11","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1182\/bloodadvances.2023009885","article-title":"Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"},{"key":"2025021107290065600_i2590-017X-8-2-99-b12","first-page":"209","volume-title":"Principles and Practice of Transplant Infectious Diseases","author":"Pereira","year":"2018"},{"key":"2025021107290065600_i2590-017X-8-2-99-b13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","article-title":"Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"14","author":"Nagler","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025021107290065600_i2590-017X-8-2-99-b14","doi-asserted-by":"crossref","first-page":"538.e1\u2013238","DOI":"10.1016\/j.jtct.2024.01.082","article-title":"Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide","volume":"30","author":"Chor\u00e3o","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025021107290065600_i2590-017X-8-2-99-b15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2025021107290065600_i2590-017X-8-2-99-b16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4274\/tjh.galenos.2020.2020.0178","article-title":"Comparison of risk scoring systems in hla-matched related allogeneic hematopoietic stem cell transplantation: a retrospective cohort study","volume":"38","author":"Alada\u011f","year":"2021","journal-title":"Turk J Haematol"},{"key":"2025021107290065600_i2590-017X-8-2-99-b17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbmt.2016.10.017","article-title":"Hematopoietic cell transplantation comorbidity index predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34 + selected grafts for allogeneic hematopoietic cell transplantation","volume":"23","author":"Barba","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2014-01-550566","article-title":"Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality","volume":"124","author":"Sorror","year":"2014","journal-title":"Blood"},{"key":"2025021107290065600_i2590-017X-8-2-99-b19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2019.02.020","article-title":"Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes","volume":"25","author":"Bramanti","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for hematopoietic cell transplantation for hematological diseases, solid tumors and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplantat"},{"key":"2025021107290065600_i2590-017X-8-2-99-b21","doi-asserted-by":"crossref","first-page":"108160","DOI":"10.1016\/j.isci.2023.108160","article-title":"Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA","volume":"26","author":"Pang","year":"2023","journal-title":"iScience"},{"key":"2025021107290065600_i2590-017X-8-2-99-b22","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic Graft-versus-Host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"2025021107290065600_i2590-017X-8-2-99-b23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","article-title":"Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"26","author":"Im","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b24","doi-asserted-by":"crossref","first-page":"204.e1","DOI":"10.1016\/j.jtct.2022.01.020","article-title":"Post-transplantation cyclophosphamide after HLA identical compared to haploidentical donor transplant in acute myeloid leukemia: a study on behalf of GETH-TC","volume":"28","author":"Bail\u00e9n","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025021107290065600_i2590-017X-8-2-99-b25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41409-019-0547-8","article-title":"Posttransplant cyclophosphamide use in matched HLA donors: a review of literature and future application","volume":"55","author":"Fakih","year":"2019","journal-title":"Bone Marrow Transplantat"},{"key":"2025021107290065600_i2590-017X-8-2-99-b26","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev"},{"key":"2025021107290065600_i2590-017X-8-2-99-b27","doi-asserted-by":"crossref","first-page":"210.e1","DOI":"10.1016\/j.jtct.2023.11.021","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-Matched and haploidentical donor transplantation for patients with hodgkin lymphoma: a comparative study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"30","author":"Montoro","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025021107290065600_i2590-017X-8-2-99-b28","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2018-99-115689","article-title":"Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor. Blood Adv. 2018;2:1022\u20131031. Erratum in","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"key":"2025021107290065600_i2590-017X-8-2-99-b29","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41409-024-02220-7","article-title":"Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"59","author":"Oechsler","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jtct.2021.10.002","article-title":"Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: A Center for International Blood and Marrow Transplant Research Analysis","volume":"28","author":"Bhatt","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025021107290065600_i2590-017X-8-2-99-b31","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for hematopoietic stem cell transplantation for hematological diseases, solid tumors and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2025021107290065600_i2590-017X-8-2-99-b32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of nonidentical family donors","volume":"107","author":"Niederwieser","year":"2022","journal-title":"Hematologica"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/99\/3486223\/10.36401_jipo-24-25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/99\/3486223\/10.36401_jipo-24-25.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:27Z","timestamp":1765475307000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/2\/article-p99.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,11]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-24-25","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}